<SEC-DOCUMENT>0001193125-20-120347.txt : 20200529
<SEC-HEADER>0001193125-20-120347.hdr.sgml : 20200529
<ACCEPTANCE-DATETIME>20200427083856
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-20-120347
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20200427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001327273
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-373-4600

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	480 Biomedical, Inc.
		DATE OF NAME CHANGE:	20120927

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Vascular, Inc.
		DATE OF NAME CHANGE:	20110826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsenal Medical, Inc.
		DATE OF NAME CHANGE:	20090414
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g805799g77a03.gif" ALT="LOGO">
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g805799g41h23.gif" ALT="LOGO">
</P> <P STYLE="font-size:60pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">April&nbsp;27, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g805799g92g57.gif" ALT="LOGO">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>VIA EDGAR AND OVERNIGHT DELIVERY </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Paul Fischer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and Insurance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mail Stop 4720 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Lyra Therapeutics, Inc. </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment No.&nbsp;1 to Registration Statement on Form S-1 </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Filed April&nbsp;27, 2020 </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>File No.&nbsp;333-236962 </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Fischer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Lyra
Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), we are transmitting this letter in response to comments received from the staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission by
letter dated December&nbsp;4, 2019 with respect to the Company&#146;s Confidential Draft Registration Statement on Form S-1 submitted on November&nbsp;8, 2019. This letter is being submitted together with a complete copy of the Company&#146;s filed
Amendment No.&nbsp;1 (&#147;<B><I>Amendment No.&nbsp;1</I></B>&#148;) to the Registration Statement on Form S-1 (File No.&nbsp;333-236962) (as amended, the &#147;<B><I>Registration Statement</I></B>&#148;), which has been revised to address the
Staff&#146;s comments. The bold and numbered paragraph below corresponds to the numbered paragraph in the Staff&#146;s letter referred to above and is followed by the Company&#146;s response. For the Staff&#146;s convenience, we are also sending, by
courier, copies of this letter and marked copies of Amendment No.&nbsp;1 that reflect changes made to the Registration Statement. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Registration
Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>April 27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g805799g33h07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><U>Use of Proceeds, page 76 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Please revise paragraph three to provide an estimate regarding how far in the development process for
LYR-210 and LYR-220 the allocated proceeds of the offering will enable you to reach. Please also disclose whether additional funds will be necessary to complete the two trials you identify. If a material amount of other funds is necessary to
complete these trials, state the amounts and sources of such other funds. Refer to Instruction 3 of Item&nbsp;504 of Regulation S-K. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: The Company respectfully acknowledges the Staff&#146;s comment and in response has revised the disclosure on page 81 of
Amendment No.&nbsp;1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>April 27, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g805799g33h07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hope that the foregoing has been responsive to the Staff&#146;s comments and look forward
to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 617-948-6027 or Peter Handrinos at 617-948-6060 with any questions or further comments you may have regarding this filing or if you wish to discuss
the above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Wesley C. Holmes </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Wesley C. Holmes </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">of LATHAM&nbsp;&amp; WATKINS LLP </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosures </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: (via e-mail) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maria Palasis, Chief Executive Officer, Lyra Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter N. Handrinos, Latham&nbsp;&amp; Watkins LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g805799g33h07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g33h07.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M)$I92P P/0$\T 4]9\9:!H%\EEJ-\4NG3>(8H9)6"YQN(13M'N<4 ;P.1D4
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MPW>IMK#GMY30DD?]_<4 :'PKNKC7-=6XO05?PYI:Z4^__GMYC;S_ -\QI^=
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M??;OLL/VO9Y?G[!OV9SMW=<9[4 -AT^RMOM'D6<$7VAB\VR,+YC'J6QU/UH
M7[!9_8/L'V2#['L\OR/+'E[?[NWICVH 5[&TD%N'M86%L0T(,8/E$# *^G''
M% "S6MO</"\\$<KPMOC9T!*-C&1GH<$\B@!L=A9PW$]Q%:0I/<8\Z18P&DQP
M-QZG\: &_P!F6!T\:>;&W^Q  "W\I?+ !R/EQCKS0 Z>QL[FX@N+BUAEFMR3
M#(\89HR>I4GI^% %>XT'1[O44U&YTFRFOH\;+B2W1I%QTPQ&10!H4 % !0!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g805799g41h23.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g41h23.gif
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MA_)&:,>!6/L(>X9]_OP Q_1'%24L2_1M5==77T@(.?7M\-Q@NQ^P5A:<T/?
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MP@45()I#@T?7!$P-6PE !4]+TBX<'N1Y@DU )>)2&PO8Y6 _^(B,"A*7-"A
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7@QSH0#%.X0%J>R >( 1!"+HT=4   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g805799g77a03.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g77a03.gif
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F*[;G38L!!B;L=QD==(@WD8#):E80L @Q&\1*%=*RT#=>'A0! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g805799g92g57.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g805799g92g57.gif
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
